Astrophys J 2006, 636:261–266.CrossRef 34. Daemen T, Hofstede G, Ten Kate MT, Bakker-Woudenberg IAJM, Scherphof GL: Liposomal doxorubicin induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int Cancer 1995, 61:761–721.CrossRef 35. Kirby
CJ, Gregoriadis G: A simple procedure for preparing liposomes capable of high encapsulation efficiency under mild conditions. In Liposome Technology. 1st edition. Edited by: Gregoriadis G. Boca Raton: CRC; 1984:19–27. 36. Alpes H, Allmann K, Plattner H, Reichert J, Rick R, Schulz S: Formation HDAC activation of large unilamellar vesicles using alkyl maltoside detergents. Biochim Biophys Acta 1986, 862:294.CrossRef 37. Gabizon AA: Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 2001, 7:223. 38. Romberg B,
Hennink WE, Storm G: Sheddable coatings for long-circulating nanoparticles. Pharm Selleckchem C188-9 Res 2008,25(1):55–71.CrossRef 39. Mayer ID, Madden TM, Bally MU, Cullis PR: pH gradient-mediated drug entrapment in liposomes. In Liposome Technology. 2nd edition. Edited by: Gregoriadis G. Boca Raton: CRC Press; 1993:27–44. 40. Arcadio C, Cullis PR: Recent advances in liposomal drug-delivery systems. Curr Opin Biotechnol 1995, 6:698–708.CrossRef 41. Awada A, Gil T, Sales F, Dubuisson M, Vereecken P, Klastersky J, Moerman C, de Valeriola D, Piccart MJ: Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers. Anticancer Drugs 2004, 15:499–502.CrossRef 42. Babai I, Samira S, Urocanase Barenholz Y, Zakay-Rones Z, Kedar E: A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice. Vaccine 1999, 17:1223–1238.CrossRef 43. Banerjee R, Tyagi P, Li S, Huang L: Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer 2004, 112:693–700.CrossRef 44. Baselga J, Metselaar JM: Monoclonal antibodies: clinical applications: monoclonal antibodies directed against
growth factor receptors. In Principles and Selleckchem Q-VD-Oph Practice of Biological Therapy of Cancer. Edited by: Rosenburg SA. Philadelphia: Lippincott; 2000:475–489. 45. Kunisawa J, Mayumi T: Fusogenic liposome delivers encapsulated nanoparticles for cytosolic controlled gene release. J Control Release 2005, 105:344–353.CrossRef 46. Parthasarathy R, Sacks PC, Harris D, Brock H, Mehta K: Interaction of liposorae-associated all-trans-retinoic acid with squamous carcinoma cells. Cancer Chemother Pharmacol 1994, 34:527–534.CrossRef 47. Mehta K, Sadeghi T, McQueen T, Lopez-Berestein G: Liposome encapsulation circumvents the hepatic clearance mechanisms of all- trans -retinoic acid. Leuk Res 1994, 18:587–596.CrossRef 48. Gill PS, Espina M, Muggia F, Cabriales S, Tulpule A, Esplin JA, Liebman HA, Forssen E, Ross ME, Levine AM: Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.